EGFR and head and neck squamous cell carcinoma: We hypothesize that the HNSCC PDX model became insensitive to anti-PD-1 immunotherapy alone by developing multifaceted bypassing mechanisms, upregulating MET signaling pathway in addition to amplification of EGFR.